Brief: Long-Acting Injectable Antipsychotic Using Medincell’s Technology Receives FDA IND Clearance To Initiate Clinical Activities

Medincell SA

26/08/2019 16:54

Aug 26 (Reuters) - MEDINCELL SA  MEDCL.PA :
    * LONG-ACTING INJECTABLE ANTIPSYCHOTIC USING MEDINCELL’S TECHNOLOGY RECEIVES FDA IND
CLEARANCE TO
INITIATE CLINICAL ACTIVITIES
    * A FIRST-IN-HUMAN STUDY IS EXPECTED TO START IN SECOND HALF OF 2019

Source text for Eikon:  ID:nBw4MCqMFa 
Further company coverage:  MEDCL.PA 

 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))